
 
 
 
 
 
 
 
 
   
 1. the crystal form of chemical compound 1, described chemical compound 1 has structural formula: 
 
 
 
 
     
 
   
 
 2. crystal form as claimed in claim 1, wherein said crystal form produce basic X-ray diffractogram shown in Fig. 1 (a), 1 (b), 1 (c) or 1 (d). 
 
     
 
   
 
 3. crystal form as claimed in claim 1, wherein said crystal form produce basic differential scanning calorimetry (DSC) thermogram shown in Fig. 3 (a) or 4 (a). 
 
     
 
   
 
 4. crystal form as claimed in claim 1, wherein said crystal form produce substantially differential scanning calorimetry (DSC) thermogram shown in arbitrary figure to 5 (d) as Fig. 3 (b), 4 (b) or Fig. 5 (a). 
 
     
 
   
 
 5. crystal form as claimed in claim 1, wherein said crystal form produce basic thermal gravimetric analysis (TGA) thermogram shown in Fig. 6 (b) or 7 (b). 
 
     
 
   
 
 6. crystal form as claimed in claim 1, wherein said crystal form produce basic thermal gravimetric analysis (TGA) thermogram shown in Fig. 6 (a) or 7 (a). 
 
     
 7. the crystal form of chemical compound 1, described chemical compound 1 has structural formula: 
 
 
 
 Wherein said crystal form produces basic X-ray diffractogram shown in Fig. 1 (c). 
 
     
 8. the crystal form of chemical compound 1, described chemical compound 1 has structural formula: 
 
 
 
 Wherein said crystal form produces basic X-ray diffractogram shown in Fig. 1 (b) or 1 (d). 
 
     
 9. the crystal form of chemical compound 1, described chemical compound 1 has structural formula: 
 
 
 
 Wherein said crystal form produces basic X-ray diffractogram shown in Fig. 1 (a). 
 
     
 
   
 
 10. crystal form as claimed in claim 1 is characterized in that the following position, angle (2 θ angle ± 1%) among the X-ray powder diffraction figure: 
 A) 5.1 °, 10.3 °, 15.2 °, 20.8 °, 22.8 °, 26.0 ° and 31.2 ° (form I); 
 B) 4.2 °, 8.3 °, 12.5 °, 16.7 °, 20.9 °, 25.2 °, 29.5 ° and 33.8 ° (form II); Or 
 C) 4.0 °, 7.9 °, 11.8 °, 15.7 °, 23.6 ° and 27.6 ° (form III). 
 
     
 
   
 
 11. crystal form as claimed in claim 1 is characterized in that the position, following angle (2 θ angle ± 1%) among the X-ray powder diffraction figure: 5.14 °, 10.34 °, 15.20 °, 20.78 °, 22.80 °, 26.02 ° and 31.20 ° (form I). 
 
     
 
   
 
 12. crystal form as claimed in claim 1 is characterized in that the position, following angle (2 θ angle ± 1%) among the X-ray powder diffraction figure: 4.16 °, 8.32 °, 12.50 °, 16.70 °, 20.94 °, 25.20 °, 29.48 ° and 33.82 ° (form II). 
 
     
 
   
 
 13. crystal form as claimed in claim 1 is characterized in that the position, following angle (2 θ angle ± 1%) among the X-ray powder diffraction figure: 3.96 °, 7.86 °, 11.80 °, 15.74 °, 23.64 ° and 27.62 ° (form III). 
 
     
 
   
 
 14. crystal form as claimed in claim 1, wherein said crystal form are to obtain by handling chemical compound 1 with the solvent system that comprises at least a low-carbon alkyl alcohol. 
 
     
 
   
 
 15. crystal form as claimed in claim 14, wherein said solvent system comprise water and are selected from the low-carbon alkyl alcohol of methanol, ethanol and isopropyl alcohol. 
 
     
 
   
   
 
 16. as claim 14 or 15 described crystal forms, wherein said low-carbon alkyl alcohol is selected from methanol, ethanol and isopropyl alcohol. 
 
     
 
   
   
   
 
 17. as each described crystal form in the claim 14 to 16, wherein said low-carbon alkyl alcohol is a methanol. 
 
     
 
   
   
   
 
 18. as each described crystal form in the claim 14 to 16, wherein said low-carbon alkyl alcohol is an ethanol. 
 
     
 
   
   
   
 
 19. as each described crystal form in the claim 14 to 16, wherein said low-carbon alkyl alcohol is an isopropyl alcohol. 
 
     
 
   
 
 20. crystal form as claimed in claim 1, wherein said crystal form can by about 50 ℃ to about 110 ℃ temperature dry first crystal form obtain. 
 
     
 
   
 
 21. crystal form as claimed in claim 20, wherein said drying was finished between about 24 hours dry period at about 30 minutes. 
 
     
 
   
 
 22. crystal form as claimed in claim 21 is about 2 hours to about 12 hours between wherein said dry period. 
 
     
 
   
   
   
 
 23. as each described crystal form in the claim 20 to 22, wherein said first crystal form is form I. 
 
     
 
   
   
   
 
 24. as each described crystal form in the claim 20 to 22, wherein said first crystal form is form II. 
 
     
 
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
 
 25. as each described crystal form in the claim 1 to 24, it is in pure substantially form. 
 
     
 
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
 
 26. as each described crystal form in the claim 1 to 25, it is in the pure form of essence. 
 
     
 
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
 
 27. as each described crystal form in the claim 1 to 26, wherein said crystal form is crystalline substantially. 
 
     
 
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
 
 28. as each described crystal form in the claim 1 to 27, wherein said crystal form is that essence is crystalline. 
 
     
 
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
 
 29. as each described crystal form in the claim 1 to 28, wherein said crystal form has Lycoperdon polymorphum Vitt to the crystalline outward appearance of silver gray. 
 
     
 
   
   
   
   
 
 30. as each described crystal form in the claim 4,6,9 and 13, wherein said crystal form does not have other crystal form of chemical compound 1 substantially. 
 
     
 31. prepare the method for crystal form as claimed in claim 1, it comprises the steps: 
 A) obtain isolated compound 1; 
 B) handle chemical compound 1 with the solvent system that comprises low-carbon alkyl alcohol; With 
 C) separating compound 1 crystal from supernatant. 
 
     
 
   
 
 32. method as claimed in claim 31, wherein said step (a) comprising: 
 I) under the condition that causes chemical compound 1 to produce, cultivate the microorganism that produces chemical compound 1; With 
 Ii) separating compound 1 from described microorganism. 
 
     
 
   
 
 33. method as claimed in claim 32, the microorganism of wherein said generation chemical compound 1 is an antibacterial. 
 
     
 
   
 
 34. method as claimed in claim 33, wherein said antibacterial is actinomycetes. 
 
     
 
   
 
 35. method as claimed in claim 34, wherein said actinomycetes are Micremonospora or streptomyces kind. 
 
     
 
   
 
 36. method as claimed in claim 35, wherein said actinomycetes are monospore silk bacteria strain 046-ECO11, [S01] 046 or [S01U02] 046 that have IDAC numbering 070303-01,231203-01 and 070905-01 respectively. 
 
     
 37. preparation is as the method for each described crystal form in the claim 1,4,6,9 and 13, it comprises following step: 
 A) obtain the first basic crystal form of chemical compound 1; 
 B) at described first crystal form of about 50 ℃ of drying steps (a) to about 170 ℃ temperature, to produce crystal form. 
 
     
 
   
 
 38. method as claimed in claim 37, wherein step (a) comprises the steps: 
 I) obtain chemical compound 1; 
 Ii) handle the chemical compound 1 that in (a), obtains with the solvent system that comprises low-carbon alkyl alcohol; With 
 Iii) from supernatant separating compound 1 first crystal form.. 
 
     
 
   
   
 
 39. as claim 37 or 38 described methods, wherein drying steps (b) carries out under inert atmosphere. 
 
     
 
   
 
 40. method as claimed in claim 39, wherein said inert atmosphere are selected from decompression or blanket of nitrogen. 
 
     
 
   
   
   
   
 
 41. as each described method in the claim 37 to 40, wherein said drying steps (b) carries out about 30 minutes to about 110 ℃ temperature during about 24 hours at about 50 ℃. 
 
     
 
   
 
 42. method as claimed in claim 41, wherein said temperature during about 4 hours to 12 hours in about 55 ℃ to 100 ℃ 
 
     
 
   
   
   
 
 43. as claim 31,32 or 38 described methods, wherein said solvent system further comprises water. 
 
     
 
   
 
 44. method as claimed in claim 43, wherein said solvent system comprises water and methanol. 
 
     
 
   
 
 45. method as claimed in claim 43, wherein said solvent system comprises water and ethanol. 
 
     
 
   
 
 46. method as claimed in claim 43, wherein said solvent system comprises water and isopropyl alcohol. 
 
     
 
   
   
   
   
   
   
 
 47. as each described method among the claim 31-36, wherein said crystal form is form I. 
 
     
 
   
   
   
   
   
   
 
 48. as each described method among the claim 31-36, wherein said crystal form is form II. 
 
     
 
   
   
   
   
   
   
 
 49. as each described method among the claim 37-42, wherein said first crystal form is form I. 
 
     
 
   
   
   
   
   
   
 
 50. as each described method among the claim 37-42, wherein said first crystal form is form II. 
 
     
 
   
   
   
   
   
   
 
 51. as each described method among the claim 37-42,49 and 50, wherein the described crystal form of paragraph (b) is form III. 
 
     
 52. pharmaceutical composition, it comprise the treatment effective dose as each described crystal form and pharmaceutically acceptable carrier in the claim 1 to 29. 
 
     
 53. pharmaceutical composition, it comprise the treatment effective dose as each described crystal form and pharmaceutically acceptable carrier in the claim 2 to 13. 
 
     
 54. pharmaceutical composition, it comprises the crystal form as claimed in claim 10 and the pharmaceutically acceptable carrier for the treatment of effective dose. 
 
     
 55. pharmaceutical composition, it comprises the crystal form as claimed in claim 11 and the pharmaceutically acceptable carrier for the treatment of effective dose. 
 
     
 56. pharmaceutical composition, it comprises the crystal form as claimed in claim 12 and the pharmaceutically acceptable carrier for the treatment of effective dose. 
 
     
 57. pharmaceutical composition, it comprises the crystal form as claimed in claim 13 and the pharmaceutically acceptable carrier for the treatment of effective dose. 
 
     
 
   
   
   
   
   
   
 
 58. each described pharmaceutical composition in the claim 52 to 57, wherein said pharmaceutical composition is the form of oral suspension or solid orally ingestible. 
 
     
 59. a method for the treatment of the tumor symptom, it comprise to patient's administering therapeutic effective dose of this type of treatment of needs as each described crystal form in the claim 1 to 29. 
 
     
 60. a method for the treatment of the tumor symptom, it comprise to patient's administering therapeutic effective dose of this type of treatment of needs as each described crystal form in the claim 2 to 13. 
 
     
 61. a method for the treatment of the tumor symptom, it comprises the crystal form as claimed in claim 10 to patient's administering therapeutic effective dose of this type of treatment of needs. 
 
     
 62. a method for the treatment of the tumor symptom, it comprises the crystal form as claimed in claim 11 to patient's administering therapeutic effective dose of this type of treatment of needs. 
 
     
 63. a method for the treatment of the tumor symptom, it comprises the crystal form as claimed in claim 12 to patient's administering therapeutic effective dose of this type of treatment of needs. 
 
     
 64. a method for the treatment of the tumor symptom, it comprises the crystal form as claimed in claim 13 to patient's administering therapeutic effective dose of this type of treatment of needs. 
 
     
 
   
   
   
   
   
   
 
 65. as each described method among the claim 59-64, wherein said tumor symptom comprises pulmonary carcinoma, colorectal carcinoma (comprising colon cancer), CNS cancer (comprising glioma), ovarian cancer, renal carcinoma, carcinoma of prostate, breast carcinoma, hemopoietic cancer (comprising leukemia) and melanoma. 
 
     
 
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
 
 66. be used for the treatment of purposes in the medicine of tumor symptom in preparation as each described crystal form in the claim 1 to 29. 
 
     
 
   
   
   
   
   
   
   
   
   
   
   
   
 
 67. be used for the treatment of purposes in the medicine of tumor symptom in preparation as each described crystal form in the claim 2 to 13. 
 
     
 
   
 
 68. crystal form as claimed in claim 10 is used for the treatment of purposes in the medicine of tumor symptom in preparation. 
 
     
 
   
 
 69. crystal form as claimed in claim 11 is used for the treatment of purposes in the medicine of tumor symptom in preparation. 
 
     
 
   
 
 70. crystal form as claimed in claim 12 is used for the treatment of purposes in the medicine of tumor symptom in preparation. 
 
     
 
   
 
 71. crystal form as claimed in claim 13 is used for the treatment of purposes in the medicine of tumor symptom in preparation. 
 
     
 72. commercial bag, it comprises as each described crystal form in the claim 1 to 29, and the explanation about using in the tumor symptom treatment. 
 
     
 73. commercial bag, it comprises as each described crystal form in the claim 2 to 13, and the explanation about using in the tumor symptom treatment. 
 
     
 74. commercial bag, it comprises crystal form as claimed in claim 10, and describes the written document about the explanation of using in the tumor symptom treatment. 
 
     
 75. commercial bag, it comprises crystal form as claimed in claim 11, and describes the written document about the explanation of using in the tumor symptom treatment. 
 
     
 76. commercial bag, it comprises crystal form as claimed in claim 12, and describes the written document about the explanation of using in the tumor symptom treatment. 
 
     
 77. commercial bag, it comprises crystal form as claimed in claim 13, and describes the written document about the explanation of using in the tumor symptom treatment. 
 
     
 
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
 
 78., be used for the treatment of the tumor symptom as each described crystal form in the claim 1 to 29. 
 
     
 
   
   
   
   
   
   
   
   
   
   
   
   
 
 79., be used for the treatment of the tumor symptom as each described crystal form in the claim 2 to 13. 
 
     
 
   
 
 80. crystal form as claimed in claim 10 is used for the treatment of the tumor symptom. 
 
     
 
   
 
 81. crystal form as claimed in claim 11 is used for the treatment of the tumor symptom. 
 
     
 
   
 
 82. crystal form as claimed in claim 12 is used for the treatment of the tumor symptom. 
 
     
 
   
 
 83. crystal form as claimed in claim 13 is used for the treatment of the tumor symptom. 
 
   
 
 
 
 
 
 
 
 
